Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2012

01-05-2012 | Preclinical study

Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy

Authors: C. Panis, A. C. S. A. Herrera, V. J. Victorino, F. C. Campos, L. F. Freitas, T. De Rossi, A. N. Colado Simão, A. L. Cecchini, R. Cecchini

Published in: Breast Cancer Research and Treatment | Issue 1/2012

Login to get access

Abstract

Several adverse effects of chemotherapy treatments have been described, and most of these effects are associated with direct interactions between blood cells and indirect effects generated during the oxidative metabolism of antineoplastic drugs. In this study we evaluated the oxidative systemic status and hematological profiles of breast cancer patients with advanced ductal infiltrative carcinoma treated with doxorubicin (DOX) or paclitaxel (PTX) within 1 h after chemotherapy. Blood analyses included evaluation of hemogram, pro-oxidative markers, and antioxidant status. The results showed that advanced breast cancer diseased (AD) patients without previous chemotherapy presented anemia and high oxidative stress status characterized by elevated levels of lipid peroxidation and nitric oxide, and reduced catalase activity when compared with controls. DOX-treated patients exhibited increased anemia and reduced antioxidant status, which was revealed by decreases in reduced glutathione levels and the total antioxidant capacity of plasma; however, these changes did not lead to further increases in lipid peroxidation or carbonyl proteins when compared with the AD group. PTX-treated patients also showed increased anemia, lactate dehydrogenase leakage, and enhanced lipid peroxidation. These data reveal for the first time that patients subjected to chemotherapy with DOX or PTX present immediate systemic oxidative stress and red blood cell oxidative injury with anemia development. These findings provide a new perspective on the systemic redox state of AD and patients subjected to chemotherapy regarding oxidative stress enhancement and its possible involvement in the aggravation of chronic anemia.
Literature
1.
2.
Karihtala P, Soini Y (2007) Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 115:81–103PubMedCrossRef
3.
National Comprehensive Cancer Network (NCCN) (2009) NCCN clinical practice guidelines in oncology: cancer and chemotherapy-induced anemia. NCCN, USA, vol 2, p 47
4.
Saulter KH, Acharia CR, Walters KS, Redman R, Anguiano A, Garman KS, Anders CK, Mukherjee S, Dressman HK, Barry WT, Marcom KP, Olson J, Nevins JR, Potti A (2008) An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. Plos One 3(4):e1908CrossRef
5.
Mukherjee S, Banerjee SK, Maulik M, Dinda AK, Talwar KK, Maulik SK (2003) Protection against acute Adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidant s, inhibition of TNF-α expression. BMC Pharmacol 3:16PubMedCrossRef
6.
Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclins: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharm Rev 56(2):185–230PubMedCrossRef
7.
Ramanathan B, Jan KY, Chen CH, Hour TZ, Yu HJ, Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65(18):8455–8460PubMedCrossRef
8.
Doroshow JH, Davies KJA (1986) Redox cycling of anthracyclins by cardiac mitochondria: formation of superoxide anion, hydrogen peroxide and hydroxyl radical. J Biol Chem 261(7):3068–3074PubMed
9.
Niki E (2009) Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 47:469–484PubMedCrossRef
10.
Schrijvers D (2003) Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Clin Pharmacokinet 42(9):779–791PubMedCrossRef
11.
Alexandre J, Hu Y, Lu W, Pelicano H, Huang P (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67(8):3512–3517PubMedCrossRef
12.
Hadzic T, Aykin-Burns N, Zhu Y, Mitchell Z, Coleman MC, Leick K, Jacobson GM, Spitz DR (2010) Paclitaxel combined with inhibitors of glucose, hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress. Free Radic Biol Med 48:1024–1033PubMedCrossRef
13.
Fukui M, Yamabe N, Zhu BT (2010) Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo. Eur J Cancer 46(10):1882–1891PubMedCrossRef
14.
Mark M, Walter R, Osian-Meredith D, Reinhart WH (2001) Commercial taxane formulations induce stomatocytosis and increase blood viscosity. Br J Pharmacol 134:1207–1214PubMedCrossRef
15.
Iiýasova D, Mixon G, Wang F, Marcom PK, Marks J, Spasojevich I, Craft N, Arredondo F, Digiulio R (2009) Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. Biomarkers 14(5):321–325CrossRef
16.
Chala E, Manes C, Iliades H, Skaragkas G, Mouratidou D, Kapantais E (2006) Insulin resistance, growth factors and cytokine levels in overweight women with breast cancer before and after chemotherapy. Hormones 5(2):137–146PubMed
17.
Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine, 4th edn. Oxford University, New York
18.
19.
Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:474–496CrossRef
20.
Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205PubMedCrossRef
21.
Repetto M, Reides C, Carretero MLG, Costa M, Griemberg G, Llesuy S (1996) Oxidative stress in blood of HIV infected patients. Clin Chim Acta 225:107–117CrossRef
22.
Simão ANC, Suzukawa AA, Casado MF, Oliveira RD, Guarnier FA, Cecchini F (2006) Genistein abrogates pre-hemolytic and oxidative stress damage induced by 2,2′-azobis (amidinopropane). Life Sci 78:1202–1210CrossRef
23.
Gonzales-Flecha B, Lleswy S, Boveris A (1991) Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver and muscle. Free Radic Biol Med 10:93–100CrossRef
24.
Panis C, Mazzuco TL, Costa CZF, Victorino VJ, Tatakihara VLH, Yamauchi LM, Yamada-Ogatta SF, Cecchini R, Pinge-Filho P (2011) Trypanosoma cruzi: effect of the absence of 5-lipoxygenase (5-LO)-derived leukotrienes on levels of cytokines, nitric oxide and iNOS expression in cardiac tissue in the acute phase of infection in mice. Exp Parasitol 127:58–65PubMedCrossRef
25.
Oliveira JA, Cecchini R (2000) Oxidative stress of liver in hamsters infected with Leishmania (L.) chagasic. J Parasitol 86(5):1067–1072PubMedCrossRef
26.
Reznick AZ, Packer L (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994(233):357–363CrossRef
27.
Miller GL (1959) Protein determination for large numbers of samples. Anal Chem 31:964CrossRef
28.
Bates DA, Winterbourn CC (1982) Reactions of Adriamycin with haemoglobin. Superoxide dismutase indirectly inhibits reactions of the adriamycin semiquinone. Biochem J 203:155–160PubMed
29.
Alexandre J, Batteux F, Nicco C, Chereau C, Laurent A, Guillevin L, Weill B, Goldwasser F (2006) Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 119:41–48PubMedCrossRef
30.
Casado MF, Cecchini AL, Simão ANC, Oliveira RD, Cecchini R (2007) Free radical mediated pre-hemolytic injury in human red blood cells subjected to lead acetate as evaluated by chemiluminescence. Food Chem Toxicol 45:945–952PubMedCrossRef
31.
Lores-Arnais S, Llesuy S (1993) Oxidative stress in mouse heart by antitumoral drugs: a comparative study of doxorubicin, mitoxantrone. Toxicology 77(1–2):31–38
32.
Dumon MF, Freneix-Clerc M, Carbonneau MA, Thomas MJ, Perromat A, Clerc M (1994) Demonstration of the anti-lipid peroxidation effect of 3′,5′,7′, trihydroxy-4′ methoxy flavone rutinoside: in vitro study. Ann Biol Clin 52(4):265–270
33.
Barbosa DS, Cecchini R, El Kadri MZ, Dichi I (2003) Decrease oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition 19:837–841PubMedCrossRef
34.
Fossey J, Lefort D, Sorba J (1995) Free Radicals in Organic Chemistry. Wiley, New York
35.
Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424–C1437PubMed
36.
Geller DA, Billiar TR (1998) Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 17:7–23PubMedCrossRef
37.
Thomsen LL, Miles DW (1998) Role of nitric oxide in tumour progression: lessons from human tumours. Cancer Metastasis Rev 17:107–118PubMedCrossRef
38.
Fukumura D, Kashiwagi S, Jain RK (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6:521–534PubMedCrossRef
39.
Abdelmagid SA, Too CKL (2008) Prolactin and estrogen up-regulate carboxypeptidase-D to promote nitric oxide production and survival of MCF-7 breast cancer cells. Endocrinology 149:4821–4828PubMedCrossRef
40.
Saad SY, Najjar TA, Alashari M (2004) Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing administration. J Biochem Mol Toxicol 18(2):78–86PubMedCrossRef
41.
Awasthi S, Sharma R, Singhal SS, Zimniak P, Awasthi Y (2002) RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics. Drug Metab Dispos 30(12):1300–1310PubMedCrossRef
42.
Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983PubMedCrossRef
43.
44.
Colombo T, Broggini M, Garattini S, Donell MG (1981) Differential adryamicin distribution to blood components. Eur J Drug Metab Pharmacokinet 6(2):115–122PubMedCrossRef
45.
Lang PA, Huober J, Bachman C, Kempe DS, Sobiesiak M, Akel A, Niemoeller OM, Dreischer P, Eisele K, Klarl BA, Gulbins E, Lang F, Wieder T (2006) Stimulation of erythrocyte phosphatidyl serine exposure by paclitaxel. Cell Physiol Biochem 18:151–164PubMedCrossRef
46.
Peres PS, Terra VA, Guarnier FA, Cecchini R, Cecchini AL (2011) Photoaging and chronological aging profile: understanding oxidation of the skin. J Photochem Photobiol B 103(2):93–97PubMedCrossRef
Metadata
Title
Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy
Authors
C. Panis
A. C. S. A. Herrera
V. J. Victorino
F. C. Campos
L. F. Freitas
T. De Rossi
A. N. Colado Simão
A. L. Cecchini
R. Cecchini
Publication date
01-05-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1693-x

Other articles of this Issue 1/2012

Breast Cancer Research and Treatment 1/2012 Go to the issue

Epidemiology

Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO

Letter to the Editor

Not so fast: the use of incomplete data to devalue the role of mammography screening

Preclinical Study

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda®

Clinical trial

Prospective study of breast tomosynthesis as a triage to assessment in screening

Preclinical study

Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1

Epidemiology

Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits